Evaluation of gel and aqueous extract of citrullus Colocynthis in patients with type 2 diabetes

Evaluation of the efficacy of gel and aqueous extract of Citrullus colocynthis (L.) Schrad in patients with type 2 diabetes compared to placebo gel

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090317001774N8

Enrollment

Registered

2018-02-20

Start date

2018-01-10

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: The appropriate amount of formulated gel in carboxymethyl cellulose (5%) is rubbed on the forearm with area 20 cm2 per day for 30 min. Intervention 2: Intervention

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Newly diagnosed type 2 diabetic patients according to ADA-2011 criteria Cases between the age group of 18-75 years Treated with oral medication (Metformin)

Exclusion criteria

Exclusion criteria: Diabetic patients with fasting blood glucose greater than 250 mg/dL and hemoglobin A1C level higher than 9% Treatment with insulin Chronic inflammatory disease Chronic complications of diabetes Pregnancy Breastfeeding Liver, kidney and neurologic diseases

Design outcomes

Primary

Measure	Time frame
Patient's blood glucose 2 hours after breakfast. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;HbA1c measurement. Timepoint: 0-90 days after start of the intervention. Method of measurement: Chromatography- %-=?.;Measurement of serum urea in fasting state. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;Measurement of serum creatinine level in fasting state. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;Measurement of aspartate aminotransferase in serum. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;Measurement of Alanine Transferase Level in Serum. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;Measurement of alkaline phosphatase in serum. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;Measurement of bilirubin in patient serum. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-Calorie meter.;Prothrombin time. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Seconds - Serology.;Partial thromboplastin time. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Seconds - Serology.;Blood glucose after 8 hours of fasting. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.	—

Measure

Time frame

Patient's blood glucose 2 hours after breakfast. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;HbA1c measurement. Timepoint: 0-90 days after start of the intervention. Method of measurement: Chromatography- %-=?.;Measurement of serum urea in fasting state. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;Measurement of serum creatinine level in fasting state. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;Measurement of aspartate aminotransferase in serum. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;Measurement of Alanine Transferase Level in Serum. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;Measurement of alkaline phosphatase in serum. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.;Measurement of bilirubin in patient serum. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-Calorie meter.;Prothrombin time. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Seconds - Serology.;Partial thromboplastin time. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Seconds - Serology.;Blood glucose after 8 hours of fasting. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: mg/dl-spectrophotometer.

—

Secondary

Measure	Time frame
Weight. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Scale.;Blood pressure. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Barometer.;Waist. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Meter.;Medicinal effects. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Questionnaire.	—

Measure

Time frame

Weight. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Scale.;Blood pressure. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Barometer.;Waist. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Meter.;Medicinal effects. Timepoint: 0-30-60-90 days after start of the intervention. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mojgan Sanjari

Kerman University of Medical Sciences

msanjari@kmu.ac.ir+98 34 1322 2270

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026